Improvement in parameters of hematologic and immunologic function and patient well-being in the phase III RESONATETM study of ibrutinib vs ofatumumab in patients with previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma
ConclusionIbrutinib led to significant improvements in hematologic function and disease symptomatology vs ofatumumab, and can restore quality of life while prolonging survival in relapsed/refractory CLL/SLL.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
More News: Allergy & Immunology | Atrial Fibrillation | Cancer | Cancer & Oncology | Chronic Leukemia | Chronic Lymphocytic Leukemia | Hematology | Hypertension | Leukemia | Lymphoma | Myeloma | Study | Weight Loss